4 Value Stocks to Buy as Fed Rate Hikes Test Wall Street

The Federal Reserve raised its benchmark rate 25bps to a 3.75%-4.00% target range, its first increase since 2023, triggering a 631.2-point (1.2%) Dow decline and a 0.45% drop in the S&P 500. With inflation still above the Fed's 2% target, partly due to Middle East conflict-driven oil prices, the Fed signaled another hike may be possible before year-end. The article recommends value stocks screened for low price-to-cash-flow and other valuation metrics, highlighting Avnet, Centene, Signet and Lifetime Brands on strong consensus EPS-growth expectations and favorable Zacks rankings.

Analysis

A higher real-rate regime does not uniformly reward low P/CF screens: the key distinction is cash-flow durability versus cash conversion funded by working capital. AVT is most exposed to a renewed electronics inventory correction and customer financing pressure; its apparent value can disappear if distributor margins compress even modestly. LCUT has the weakest setup despite optical cheapness: small-cap liquidity, import/input-cost exposure, and seasonal inventory requirements make its free-cash-flow profile materially more rate-sensitive than operating cash flow suggests.

CNC is the cleaner defensive expression, but the investable variable is not the valuation screen—it is medical-cost trend and state-rate adequacy. If utilization or acuity rises faster than reimbursement, incremental revenue carries little earnings value; conversely, stable medical-loss ratios can drive estimate revisions and multiple re-rating over the next 1-3 quarters. SIG is a consumer-credit and discretionary-demand beta rather than a conventional value hedge: persistent restrictive policy would pressure financed-ticket demand and promotions, even if reported cash generation initially holds up through inventory reductions.

Consensus is likely over-attributing any rotation toward "value" to simple multiple arithmetic. Sustained rate volatility favors balance-sheet resilience and recurring cash flows, not low-multiple cyclicals with refinancing, inventory, or demand elasticity risk. The near-term catalyst is the next inflation and labor data sequence; over 6-18 months, a higher cost of capital should widen dispersion between CNC and the more economically sensitive AVT/SIG/LCUT rather than lift the entire screen.

Key Decisions for Investors

• Initiate a 1-3 month long CNC / short SIG pair, sized beta-neutral: CNC offers relative earnings defensiveness while SIG is more exposed to consumer financing and promotional-margin risk. Target 10-15% relative return; exit if CNC medical-cost guidance deteriorates or SIG posts positive same-store-sales and gross-margin revisions.
• Avoid LCUT as a standalone long until free-cash-flow conversion, net leverage, and inventory turns are independently confirmed in the next filing. Treat any sharp screen-driven rally as a potential short/watch candidate; liquidity and borrow availability are prerequisites.
• Maintain AVT as a watchlist long only after evidence of stabilizing distributor inventory and improving gross-margin guidance. A 3-6 month entry is warranted if end-market order trends improve without receivables growth outpacing sales; otherwise, low valuation is insufficient protection.
• Use XLP versus XLY as the broader 1-3 month expression of restrictive-policy persistence rather than adding broad value exposure. Reduce the defensive tilt if core inflation decelerates decisively and the front-end rate path reprices lower.